Increased indoleamine 2,3-dioxygenase activity in type 2 diabetic nephropathy

Area of Science:

• Nephrology
• Endocrinology
• Immunology

Background:

• Type 2 diabetic nephropathy (DN) is a major complication of diabetes, leading to kidney damage.
• The role of indoleamine 2,3-dioxygenase (IDO) in the pathogenesis of DN is not fully understood.
• Understanding factors contributing to DN progression is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the hypothesis that indoleamine 2,3-dioxygenase (IDO) plays a pathogenic role in type 2 diabetic nephropathy (DN).
• To assess the correlation between IDO activity and kidney function markers in patients with type 2 DN.
• To evaluate IDO activity across different stages of chronic kidney disease.

Main Methods:

• A study cohort of 100 individuals was recruited, including healthy controls, patients with latent glomerulonephritis, type 2 DN patients with varying eGFR, and maintenance hemodialysis patients.
• Clinical parameters, including serum creatinine, estimated glomerular filtration rate (eGFR), L-tryptophan, L-kynurenine, and 24h urinary protein, were collected and analyzed.
• IDO activity was measured and correlated with age, eGFR, and disease status.

Main Results:

• IDO activity was significantly related to eGFR (r=-0.54, P=0.002), showing a negative correlation.
• IDO activity was higher in type 2 DN patients with eGFR >60ml/min/1.73m² (Group C1) compared to controls and glomerulonephritis patients (P=0.003 and P=0.008, respectively).
• IDO activity was lower in Group C1 compared to maintenance hemodialysis patients (P=0.003).

Conclusions:

• IDO activity increases with the severity of chronic kidney disease and negatively correlates with eGFR.
• Significantly elevated IDO activity in type 2 DN patients with eGFR >60ml/min/1.73m² suggests a role in early-stage DN pathogenesis.
• IDO may be closely implicated in the pathological processes of type 2 diabetic nephropathy.